Ligatend Liquescence Liquid
NDC Package 83027-0149-1
Package Information
Ligatend Liquescence (hypericum perforatum, ruta graveolens, arnica montana, bryonia (alba), chondroitin sulfate, collagen, eupatorium perfoliatum, medulla ossis suis, rhus tox, manganum metallicum, magnesium phosphorica) liquids is • Adults: 1 to 2 teaspoons, one to two times daily. This formulation utilizes a liquid delivery system. Marketed by Nutritional Specialties, Inc., this product is identified by NDC 83027-0149.
Identification & Billing
Clinical Specifications
- ARNICA MONTANA WHOLE 6 [hp_X]/mL
- BRYONIA ALBA ROOT 6 [hp_X]/mL
- CHONDROITIN SULFATE (BOVINE) 6 [hp_X]/mL
- EUPATORIUM PERFOLIATUM FLOWERING TOP 6 [hp_X]/mL
- HYDROLYSED BOVINE COLLAGEN (ENZYMATIC 6 [hp_X]/mL
- 3500 MW) 3 [hp_X]/mL
- HYPERICUM PERFORATUM WHOLE 12 [hp_X]/mL
- MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE 12 [hp_X]/mL
- MANGANESE 3 [hp_X]/mL
- RUTA GRAVEOLENS FLOWERING TOP 6 [hp_X]/mL
- SUS SCROFA BONE MARROW 6 [hp_X]/mL
- TOXICODENDRON PUBESCENS LEAF
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 83027 - Nutritional Specialties, Inc.
- 83027-0149 - Ligatend Liquescence
- 83027-0149-1 - 120 mL in 1 BOTTLE, GLASS
- 83027-0149 - Ligatend Liquescence
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83027-0149-1 identifies a specific commercial package of 120 ml in 1 bottle, glass of Ligatend Liquescence, a human over the counter drug labeled by Nutritional Specialties, Inc.. This liquid is formulated for oral use and contains arnica montana whole; bryonia alba root; chondroitin sulfate (bovine); eupatorium perfoliatum flowering top; hydrolysed bovine collagen (enzymatic; 3500 mw); hypericum perforatum whole; magnesium phosphate, dibasic trihydrate; manganese; ruta graveolens flowering top; sus scrofa bone marrow; toxicodendron pubescens leaf as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nutritional Specialties, Inc. on April 14, 2025. The current certification is valid through December 31, 2026.
How is this Nutritional Specialties, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83027014901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.